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Acute Myeloid Leukaemia [AML] proliferation is dependent on a complex multi-
faceted interplay between the blasts and the bone marrow microenvironment (1). We 
and others have previously demonstrated that functional mitochondria are 
transferred from the MSC to the AML blasts facilitating progression of the disease (2, 
3), in a process which is hijacked from haematopoietic stem cell response to 
infection (4). Clinical observations trials using Venetoclax, which targets BCL2 
(which in turn is a key regulator of the mitochondrial apoptotic pathway), in 
combination with hypomethylating agents showed tolerable safety and favorable 
overall response rate in elderly patients with AML (5). Taken together these data 
imply that mitochondria represent an attractive and biologically plausible drug target 
in the treatment of AML. 
CD38 is a transmembrane glycoprotein which is expressed on many cells of the 
haematopoietic system including malignant plasma cells, red blood cells, myeloid 
cells, lymphoid cells and subsets of leukaemia initiating AML blasts (6-8).  
Furthermore we have recently shown that CD38 mediates pro-tumoral mitochondrial 
transfer from mesenchymal stromal cells (MSC) to malignant plasma cells in 
myeloma (9), which in part explains why Daratumumab (an anti-CD38 monoclonal 
antibody) is clinically effective in treating patients with myeloma (10). More recently, 
daratumumab has been shown to have preclinical activity in AML (11). Therefore, 
taken together we hypothesise that daratumumab treatment would impair AML 
metabolic capacity and consequently inhibit tumour proliferation, via a mechanism 
which blocks mitochondrial transfer from BMSC to the blasts. 
Initially, to determine if CD38 inhibition blocks mitochondrial transfer from MSC to 
AML blasts, we used an in vitro co-culture system. MitoTracker Green FM stain was 
used to quantify mitochondria in AML after coculture with MSC. We incubated both 
MSC and AML with MitoTracker Green FM. The cells were washed twice in PBS and 
incubated for 4 h. The cells were then cocultured for 24 h with and without 
darartumumab. AML was shown to have less MitoTracker fluorescence when treated 
with daratumumab, using flow cytometry (Figure 1A-C). Figure 1D shows the 
presence of mouse mtDNA in human AML after co-culture with mouse MSC and the 
transfer of mouse mtDNA to human AML was inhibited by the addition of 
daratumumab.  We further showed that knockdown of CD38 inhibited mitochondrial 
content in AML when cultured with MSC (figure1E and F). We next investigated if 
daratumumab could inhibit AML disease progression in vivo. To do this we used an 
NSG mouse model of AML whereby on day 1 we transplanted 0.5x106 OCI-AML3 
cells tagged with a luciferase construct into the tail vein of NSG mice (3), we then 
treated the NSG animals with either vehicle control (PBS) or daratumumab (5mg/kg) 
on day 9 and day 16 by intra-peritoneal (IP) injection (Figure 2A). The mice were 
then imaged using bioluminescence on day 21. Figure 2B shows bioluminescence 
from live in-vivo imaging. The pre-treatment tumor burden was the same between 
treatment and control animals on day 9, however following treatment with 
daratumumab the tumor burden in treated animals was significantly reduced when 
compared to mice in the vehicle control group.  The densitometry measurement of 
these images are in figure 2C to illustrate the differences between vehicle and 
daratumumab treated animals. These data show that there was less tumor derived 
bioluminescence intensity in the daratumumab treated animals when compared to 
control. Daratumumab treated animals also had increased overall survival compared 
to controls animals (Figure 2D).  
To determine how daratumumab altered the metabolic profile and function of the 
AML cells in vivo we again transplanted 0.5x106 OCI-AML3-luc cells and treated the 
mice as described in Figure 2.  The mice were then sacrificed on day 21 and OCI-
AML3-luc cells were isolated by cell sorting from mouse bone marrow and the cells 
were analysed ex vivo (Figure 3A). The mitochondrial mass within the OCI-AML3-luc 
cells was not significantly reduced in the animals treated with daratumumab 
compared to the control animals (Figure 3B). Mitochondrial potential measured by 
Tetramethylrhodamine, Methyl Ester, Perchlorate (TMRM) staining shows that the 
OCI-AML3-luc cells had a reduced mitochondrial potential in the daratumumab 
treated animals compared to the control vehicle treated NSG mice (Figure 3C). To 
determine whether daratumumab altered mitochondrial based metabolism we 
analysed the OCI-AML3-luc cells isolated from the vehicle control and the 
daratumumab treated animals and then measured oxygen consumption rate (OCR) 
using the Seahorse Cell Mito Stress Test assay. Figure 3D shows decreased 
mitochondrial respiration was observed in the OCI-AML3-luc cells from 
daratumumab treated animals compared to OCI-AML3-luc cells from control treated 
mice. To investigate if mitochondrial transfer from the bone marrow 
microenvironment to the AML was altered with daratumumab treatment the human 
OCI-AML3-luc cells were isolated from murine bone marrow by cell sorting and 
analysed for the presence of mouse mitochondrial DNA within the human OCI-
AML3-luc cells by TaqMan Real-time PCR. Figure 3E confirms that daratumumab 
treatment inhibited mouse mitochondrial DNA transfer to human OCI-AML3-luc cells. 
Together, these results reason, in vivo, that daratumumab treatment causes OCI-
AML3-luc cells to have a decrease in AML mitochondrial mass, reduction of AML 
transfer from MSC to AML blasts and may contribute to the inhibitory functional bio-
energetic consequence in AML metabolism in the bone marrow microenvironment.  
In conclusion, CD38 inhibition results in reduced mitochondrial transfer from MSC to 
AML blasts in the BM microenvironment, resulting in a reduction in AML derived 
oxidative phosphorylation and subsequent reduced tumor burden. While it is likely 
that daratumumab functions through a number of mechanisms of action, here we 
show in an NSG mouse model lacking functional B cells, T cells and NK cells, that 
inhibition of mitochondrial transfer can be added to the list of mechanisms of action 
for this drug in AML. These data support the further investigation of daratumumab as 
a therapeutic approach for the treatment of mitochondrial dependent tumour growth.  
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Figure legends 
 
Figure 1. CD38 inhibition blocks mitochondrial transfer from MSC to AML 
blasts. (A) Primary AML and MSC were pre-stained with MitoTracker green FM for 
1hour and then cultured alone or together for 24 hours. Flow cytometry was used to 
detect MitoTracker green FM in the AML blasts (n=8). (B) Primary AML and MSC 
were pre-stained with MitoTracker green FM for 1hour and then cultured together for 
24hours in the presence of vehicle or daratumumab (100ng/ml). Flow cytometry was 
used to detect MitoTracker green FM in the AML blasts (n=6). (C) Primary AML were 
pre-stained with MitoTracker green FM for 1 hour and then treated with vehicle or 
daratumumab for 24 h (100ng/ml). Flow cytometry was used to detect MitoTracker 
green FM in the AML blasts (n=5).  (D) Human AML was cultured with mouse MSC 
in the presence of vehicle or daratumumab for 24 h (100ng/ml) for 24 hours. AML 
were isolated and measured for mouse mitochondrial DNA content.  Primary AML 
were transduced with CD38 targeted shRNA for 48 hours. (E) RNA was then 
extracted and examined for CD38 mRNA expression. (F)  AML and MSC were then 
pre-stained with MitoTracker green FM for 1hour and then cultured together for 24 
hours. Flow cytometry was used to detect MitoTracker green FM in the AML blasts 
(n=4). We used the Mann-Whitney U test and Wilcoxon matched pairs signal rank 
test, to compare results between groups 
 
Figure 2. Daratumumab inhibits AML disease progression in vivo. (A) 
Schematic of. the in-vivo model for these experiments. (B) 0.5x106  OCI-AML3-luc 
cells were injected into the tail vein  of NSG mice. Mice were imaged using 
bioluminescence at day 9 following injection to confirm tumor engraftment, and then 
split into two groups. Group 1 received vehicle (PBS) and group 2 received 
daratumumab (Dara; 5mg/kg) on day 9 and day 16 by intra-peritoneal (IP) injection. 
Mice were then imaged using bioluminescence at day 21 and then sacrificed. (C) 
Densitometry of the bioluminescent images shown in (B) was performed to 
determine differences between vehicle and daratumumab treated animals. (D) In a 
separate experiment, Kaplan-Meier survival curves for C57BL/6 (n=5) mice injected 
with 0.5x106  OCI-AML3-luc and then treated with vehicle or daratumumab at day 9 
and 16 post injection, was performed. We used the Mann-Whitney U test to compare 
results between groups. The Mantel-Cox test was used to analyse Kaplan-Meier 
survival curves. 
 
Figure 3. Daratumumab alters the metabolic function of AML cells in vivo. (A) 
Schematic of the in-vivo model for these experiments.  0.5x106  OCI-AML3-luc cells 
were injected into the tail vein of NSG mice. Mice were imaged using 
bioluminescence at day 9 following injection to confirm tumor engraftment, and then 
split into two groups. Group 1 received vehicle (PBS) and group 2 received 
daratumumab (Dara; 5mg/kg) treatment on day 9 and day 16 by intra-peritoneal (IP) 
injection. Mice were then sacrificed at day 21 and OCI-AML3-luc cells were isolated 
by cell sorting from mouse bone marrow and analysed for (B) Mitochondrial content 
by MitoTracker Green staining. (C) Mitochondrial potential by Tetramethylrhodamine, 
Methyl Ester, Perchlorate (TMRM) staining. (D) Oxygen consumption rate (OCR) by 
Seahorse Cell Mito Stress Test kit. (E) Presence of mouse mitochondrial DNA by 
Real-time PCR. We used the Mann-Whitney U test to compare results between 
groups 
 
 



